Disclosure of Antibody’s Equivalents Not Necessary to Satisfy Written Description and Indefiniteness Requirements for a Means-Plus-Function Claim Term

The United States Patent and Trademark Office’s (“USPTO”) Appeals Review Panel (“the Panel”) recently clarified that means-plus-function claims do not require that the specification disclose equivalents. See Ex parte Chamberlain, No. 2022-001944 (P.T.A.B. May 21, 2024) (“Panel Decision”), 35–37….
By: WilmerHale
Previous Story

California Uber Accidents and Personal Injury Claims

Next Story

Technological Challenges for Regulatory Thresholds of AI Compute